Status:
COMPLETED
An Observational Study For Ambrisentan
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
Brief Summary
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
Detailed Description
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
Eligibility Criteria
Inclusion
- subjects who have been prescribed ambrisentan for a medically appropriate use (see approved product label)
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00679224
Start Date
June 1 2008
End Date
July 1 2013
Last Update
March 23 2017
Active Locations (112)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Darlinghurst, New South Wales, Australia, 2010
2
GSK Investigational Site
Chermside, Queensland, Australia, 4032
3
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
4
GSK Investigational Site
Brussels, Belgium, 1070